健康元:健康元药业集团股份有限公司2022年第一季度报告（英文版）

Joincare Pharmaceutical Group Industry Co. Ltd. 2022 First Quarterly Report
Stock code：600380 Stock abbreviation：健康元
Joincare Pharmaceutical Group Industry Co. Ltd
2022 First Quarterly Report
Board of Directors (the “Board”) and all Directors of the Company hereby warrant that there are no
false representations misleading statements or material omissions contained in this report and
severally and jointly accept responsibility for the truthfulness accuracy and completeness of the
contents of the Report.IMPORTANT NOTICE
(I) The Board the Supervisory Committee and the Directors Supervisors and senior management
of the Company hereby warrant the truthfulness accuracy and completeness of the contents of
quarterly reports and that there are no false representations misleading statements or material
omissions contained in the Report and severally and jointly accept responsibility.(II) The person-in-charge of the Company the person-in-charge of the Company's accounting work
and the person-in-charge of the accounting department (the head of the accounting department)
hereby warrant the truthfulness accuracy and completeness of the financial statements
contained in quarterly reports.(III) Whether the first quarterly financial statements are audited
□Applicable √N/A
(IV) The Report is prepared in both Chinese and English. In case of any ambiguity in the
understanding of the Chinese and English texts the Chinese version shall prevail.I Principal Financial Data
(I) Principal accounting data and financial indicators
Unit: Yuan Currency: RMB
The Reporting Period:
Item Year-on-Year Change (%)
(January-March 2022)
Revenues 4657343538.89 12.36
Net profit attributable to Shareholders of
460537813.5325.52
the listed company
Net profit attributable to Shareholders of
the listed company after deducting the 457193702.95 36.47
extraordinary gain or loss
Net cash flow from operating activities 871904476.98 76.27
Basic earnings per share (RMB/share) 0.2411 28.49
Diluted earnings per share (RMB/share) 0.2410 28.72
Weighted average return on net assets (%) 3.84 Increased by 0.58 percentage points
1 / 16Joincare Pharmaceutical Group Industry Co. Ltd. 2022 First Quarterly Report
Change from the end
End of the of the previous year to
End of the Previous Year
Reporting Period the end of the
Reporting Period (%)
Total assets 32275092753.15 31103900389.29 3.77
Owners’ equity attributable
to Shareholders of the listed 12073975596.59 11820293656.69 2.15
company
Note: During the Reporting Period the Company recorded revenues of RMB 4657 million
representing an increase of 12.36% year-on-year; the main driver of the growth is steady increasing
sales volume of main product categories in key specialist arenas. During the first quarter of 2022
Revenues from chemical drug preparation products amounted to RMB 2737 million representing
an increase of 24.54% year-on-year of which Revenues from Inhalation products amounted to 363
million representing an increase of 324.90% year-on-year; Revenues from anti-infective drugs
amounted to RMB 350 million representing an increase of 26.91% year-on-year; Revenues from
gastroenterology products amounted to RMB 1070 million representing an increase of 5.90% year-
on-year; Revenues from gonadotropic hormones products amounted to RMB 737 million
representing an increase of 22.84% year-on-year; Revenues from APIs and intermediates amounted
to RMB 1406 million representing an increase of 14.90% year-on-year. The Revenues from
traditional Chinese medicine preparations amounted to RMB 283 million representing a decrease
of 33.53% year-on-year. The Revenues from diagnostic reagents and equipment products amounted
to RMB162 million representing a decrease of 30.77% year-on-year.(II) Items and amounts of extraordinary gains and losses
Unit: Yuan Currency: RMB
Amounts for the
Item Explanation
Reporting Period
Gains and losses on disposal of non-current Proceeds from disposal of fixed
-374417.51
assets assets
Government grants included in profit and
loss for the Period (except for government
grants closely associated with normal Government grants through the
56644887.24
corporate businesses entitled at fixed profits and losses for the Period
amount or fixed level according to national
policies and national unified standards)
Gains and losses on fair value changes
derived from holding of financial assets held
for trading derivative financial assets
financial liabilities held for trading Gains or losses arising from
derivative financial liabilities and changes in fair value of financial
investment income generated on disposal of assets/liabilities held for trading
-45275532.62
financial assets held for trading derivative and investment gains from holding
financial assets financial liabilities held for and disposal of financial
trading derivative financial liabilities and assets/liabilities held for trading
other debt investments except for effective
hedging activities related to the ordinary
operating business of the Company
Other non-operating Revenues and non- Other non-operating Revenues and
operating expenditures apart from the above 241415.42 non-operating expenditures apart
items from the above items
Effect of the above items on
Less: Income tax effect 9124665.76
income tax
The portion of the above items to
Effect of minority interests after tax -1232423.81 which minority shareholders are
entitled
Total 3344110.58
2 / 16Joincare Pharmaceutical Group Industry Co. Ltd. 2022 First Quarterly Report
The explanation on the recognitions of the items of extraordinary gains and losses as set out in the“Interpretative Announcement for Information Disclosure of Companies that Issue Securities to thePublic No. 1 – Extraordinary Gains or Losses” as items of recurring gains and losses
□Applicable √N/A
(III) Changes and the reasons for changes in principal accounting data and financial indicators
√Applicable □N/A
Name of item Change in proportion（%） Explanation
Net profit attributable to Mainly due to the growth of the sales
Shareholders of the listed revenues from the chemical drugs and
36.47
company after deducting the APIs products which is the main driver
extraordinary gain or loss of the growth of the net incomes.Net cash flow from operating Mainly due to an increase of cash
76.27
activities collections of sales revenues.（IV）Substantial changes of other items in the Financial Statements and financial indicators and
reasons thereof
Unit: Yuan Currency: RMB
Change in
Balance Sheet 2022/03/31 2021/12/31 proportion Main Reason
（%）
Short-term loans 1655807901.10 2518484835.09 -34.25 Mainly due to repayment of loans in the Period.Mainly due to part of the contract payments received
Contract liabilities 124089632.31 234140702.29 -47.00 in advance in the Period which met the conditions for
revenue recognition were transferred to revenues.Mainly due to an increase in enterprise income tax
Taxes payables 382548978.08 270618183.41 41.36
payables.Mainly due to an increase of new long-term loans by
Long-term loans 1816661809.48 826780252.78 119.73
subsidiaries in the Period.Mainly due to the share repurchased during the current
Treasury shares 472590296.96 222644454.50 112.26
period.Other
Mainly due to the disposal of stocks of China Galaxy
comprehensive -87498451.08 5387545.97 -1724.09
Securities Co. Ltd. held during the Period.income
Change in
Income Statement 2022 Jan.-Mar. 2021 Jan.-Mar. proportion Main Reason
（%）
Mainly due to the increase in the investment incomes
Investment incomes 29176808.52 21812732.70 33.76
from associate investments held in the current period.Gains from changes Mainly due to fluctuations in the market value of subject
-54151999.18 -39393074.92 N/A
in fair value securities investment held.Mainly due to the recovery of the accounts receivables
Credit impairment with relatively long ages in the current period which
217773.10 -3611272.93 N/A
loss offset the expected credit losses accrued in the previous
period.Mainly due to a decrease in the provision for inventory
Asset impairment
-5309013.21 -22802167.34 N/A depreciation in the current period as compared with the
loss
previous period.Gains from disposal Mainly due to losses occurred from disposal of fixed
-370357.7121927.78-1788.99
of assets assets in the current period.Non-operating
2321933.96 24072371.67 -90.35 Mainly due to the land disposal in the previous period.
income
Non-operating Mainly due to larger non-profit donation expenditure in
2084578.343257611.14-36.01
expenditure the previous period.Other
comprehensive net Mainly due to changes in the fair value of other equity
-106847774.60 -166618134.73 N/A
income after instrument investments.taxation
3 / 16Joincare Pharmaceutical Group Industry Co. Ltd. 2022 First Quarterly Report
Change in
Cash Flow
2022 Jan.-Mar. 2021 Jan.-Mar. proportion Main Reason
Statement
（%）
Net cash flow from Mainly due to an increase of cash collections of sales
871904476.98494649514.2576.27
operating activities revenues.Mainly due to the increase in cash inflow from
Net cash flow from
investing activities caused by the disposal of stocks of
investment -77907837.67 -269420918.38 N/A
China Galaxy Securities Co. Ltd. held during the
activities
Period.Net cash flow from Mainly due to an increase of new long-term loans in
62714553.34 -542754908.85 N/A
financing activities the current period.Effect of changes in
Mainly due to an increase of exchange losses on
foreign exchange
-12259201.98 3666733.44 -434.34 foreign currency funds held as a result of the
rates on cash and
fluctuations in exchange rates.cash equivalents
Net increase in cash Mainly due to an increase of cash from daily operating
and cash 844451990.66 -313859579.54 N/A activities of the Company and an increase of new long-
equivalents term loans.II Shareholders' Information
(I) Table of the total number of ordinary shareholders the number of preferred shareholders with
resumed voting rights and shareholdings of the top 10 shareholders
Unit: Shares
Total number of preferred
Total number of ordinary
shareholders with resumed voting
shareholders at the end of 102434 0
rights at the end of the Reporting
the Reporting Period
Period (if any)
Shareholdings of the top 10 shareholders
Number of Pledge mark or lock-up
Nature of Number of Percentage shares held
Name of shareholders Share
shareholders shares (%) with selling Number
status
restrictions
Domestic
Shenzhen Baiyeyuan
non-state-
Investment Co. Ltd. * (深圳 895653653 46.85 0 Pledge 95679725
owned legal
市百业源投资有限公司)
person
Hong Kong Securities
Unknown 127833815 6.69 0 Unknown
Clearing Company Limited
Overseas legal
Might Seasons Limited 57487434 3.01 0 Unknown
person
108 portfolio of national
Unknown 11461721 0.60 0 Unknown
social security fund
Huaxia Life Insurance Co.Unknown 9275718 0.49 0 Unknown
Ltd. - proprietary fund
16011 portfolio of basic
Unknown 9050234 0.47 0 Unknown
endowment insurance fund
Bosera Funds Management
Co. Ltd. - 419 portfolio of Unknown 8732946 0.46 0 Unknown
social security funds
Domestic
He Zhong 7800024 0.41 0 Unknown
natural person
Abu Dhabi Investment Overseas legal
5417816 0.28 0 Unknown
Authority person
Agricultural Bank of China
Limited - China 500
Exchange Traded Open-End Unknown 4690194 0.25 0 Unknown
Index Securities Investment
Fund (ETF)
4 / 16Joincare Pharmaceutical Group Industry Co. Ltd. 2022 First Quarterly Report
Shareholdings of the top 10 shareholders without selling restrictions
Number of tradable Class and number of shares
Name of shareholders shares held without
Class Class
selling restrictions
Shenzhen Baiyeyuan Investment Co. Ltd. * Ordinary shares
895653653895653653
(深圳市百业源投资有限公司) denominated in Renminbi
Hong Kong Securities Clearing Company Ordinary shares
127833815127833815
Limited denominated in Renminbi
Ordinary shares
Might Seasons Limited 57487434 57487434
denominated in Renminbi
Ordinary shares
108 portfolio of national social security fund 11461721 11461721
denominated in Renminbi
Huaxia Life Insurance Co. Ltd. - proprietary Ordinary shares
92757189275718
fund denominated in Renminbi
16011 portfolio of basic endowment insurance Ordinary shares
90502349050234
fund denominated in Renminbi
Bosera Funds Management Co. Ltd. - 419 Ordinary shares
87329468732946
portfolio of social security funds denominated in Renminbi
Ordinary shares
He Zhong 7800024 7800024
denominated in Renminbi
Ordinary shares
Abu Dhabi Investment Authority 5417816 5417816
denominated in Renminbi
Agricultural Bank of China Limited - China
Ordinary shares
500 Exchange Traded Open-End Index 4690194 4690194
denominated in Renminbi
Securities Investment Fund (ETF)
There was no connection or acting-in-concert relationship between
Description of connection or acting-in-concert Shenzhen Baiyeyuan Investment Co. Ltd. the controlling shareholder
relationship of the above shareholders of the Company and other shareholders; whether there is connection or
acting-in-concert relationship among other shareholders is unknown.Description of the participation of the top 10
Shareholder He Zhong held 800000 shares through an ordinary
shareholders and the top 10 shareholders
securities account and 7000024 shares through a customer's margin
without selling restriction in securities margin
account namely 7800024 shares in total.trading and securities financing (if any)
As at the end of the Reporting Period the special repurchase account of
Notes on the special repurchase account among the Company (special securities repurchase account of Joincare
the top 10 shareholders Pharmaceutical Group Industry Co. Ltd.) owned 38402584 shares in
total accounting for 2.01% of total share capital of the Company.III Other Information
Other key information on the operations of the Company during the Reporting Period to which
investors should be reminded to pay attention
√Applicable □N/A
1.Use of proceeds
Pursuant to the “Resolution on Change of Certain Projects Invested with Proceeds” considered
and approved at the 8th meeting of the 8th Session of the Board of the Company on 24 January
2022 it was agreed that Zhuhai Health Industry Base Construction Project was changed to the New
Product R&D Project Haibin Pharma Pingshan Pharmaceutical Industrialization Base Expansion
Project and the Information Platform Construction Project. The resolution was approved at the 2022
1st extraordinary general meeting of the Company on 11 February 2022.
Before the alteration of the projects invested with the Proceeds is as follows:
5 / 16Joincare Pharmaceutical Group Industry Co. Ltd. 2022 First Quarterly Report
Unit: 10000 Yuan
Total Total amount Use of proceeds Balance of
Project name amount of of proceeds as at 31 proceeds as at 31
investment investment December 2021 December 2021
Zhuhai Health Industry Base ConstructionProject（珠海大健康产业基地建设项 98066.84 76974.02 3386.29 73587.73目）
Haibin Pharma Pingshan PharmaceuticalIndustrialization Base Project（海滨制药 125471.35 90000.00 66745.58 23254.42坪山医药产业化基地目）
Total 223538.19 166974.02 70131.87 96842.15
Given the facts that the “Zhuhai Health Industry Base Construction Project” has been
postponed for several times for not meeting the conditions for commencement and the market
environment and the Company's business situation have changed which resulted in changes in the
project feasibility that the Company has an urgent need of funds for R&D investment and other
projects and that other financing channels are time-consuming and costly the Company changed
the aforementioned project to the New Product R&D Project Haibin Pharma Pingshan
Pharmaceutical Industrialization Base Expansion Project and the Information Platform Construction
Project. See below for details:
Unit: 10000 Yuan
Before alteration After alteration
Total
Total Total amount
Total amount amount of
Project name amount of of proceeds Project name
of investment proceeds
investment investment
investment
New Product R&D Project
110000.0054587.73
(新产品研发项目)
Haibin Pharma Pingshan
Zhuhai Health Pharmaceutical
Industry Base Industrialization Base
18139.3916000.00
Construction Project 98066.84 76974.02 Expansion Project (海滨制
（珠海大健康产业药坪山医药产业化基地扩基地建设项目）建项目)
The Information Platform
Construction Project (信息 3000.00 3000.00
化平台建设项目)
Total 98066.84 76974.02 Total 131139.39 73587.73
The details of alteration of the projects invested as follows:
(1) The New Product R&D Project
The total investment amount of the project is RMB 1100000000 in which RMB 545877300
is raised mainly for the research and development of inhalation preparations complex injections
and new drug delivery devices among others. In particular the investment is used to acquire R&D
equipment pre-clinical and clinical R&D inputs. Main products involved in this project are: 1)
Respiratory drugs: the main purpose of the project as a part of the Company's strategic layout in the
respiratory drug market in a bid to increase sources of profit and enhance the Company's
comprehensive competitiveness in the pharmaceutical market; 2) Complex injections: mainly
6 / 16Joincare Pharmaceutical Group Industry Co. Ltd. 2022 First Quarterly Report
micronano injections. The Company has built a complex injection technology development platform
specializing in the development of special injection products such as nanocrystals microcrystals
liposomes and emulsions. The micronano preparations proposed with this platform will be
developed based on existing drugs with exact clinical value to further expand the clinical use of the
drug; 3) New drug delivery devices: to be developed based on the progress of R&D of drugs for
respiratory diseases so as to improve the industrial chain of core products and enhance the added
value and core competitiveness of products to be marketed.
(2) Haibin Pharma Pingshan Pharmaceutical Industrialization Base Expansion Project
The total investment amount of this project is RMB 181393900 in which RMB 160000000
is raised. Expanded from the Haibin Pharma Pingshan Pharmaceutical Industrialization Base
Expansion Project this project established new production lines of Tobramycin Solution for
Inhalation Fluticasone Propionate Suspension for Inhalation among others and expanded existing
production lines of Budesonide Suspension for Inhalation and Levosalbutamol Hydrochloride
Nebuliser Solution. This project is implemented for two key reasons: 1) New products are to be
marketed which requires related production lines. With inhalation preparations incorporated in its
key layout in recent years the Company has continuously invested in the R&D of several new
products with high clinical value and broad market space. As new products like Tobramycin
Solution for Inhalation and Fluticasone Propionate Suspension for Inhalation are to be marketed
related production lines are necessary to make preparation for commercial production. 2) The
capacity is unable to meet demand of some products: Budesonide Suspension for Inhalation was
involved in the fifth batch of national centralized drug procurement in June 2021 and will be
supplied to public hospitals in 7 domestic provinces meeting 70% of the drug needs according to
policies. Levosalbutamol Hydrochloride Nebuliser Solution is the first approved exclusive generic
drug in China. As at the date the resolution got approved (January 24 2022) no originator
manufacturers or other generic drug manufacturers have been approved for market in China.However the market demand is huge. The original capacity of the above two products is unable to
meet such market demand making capacity expansion a must.
(3) The Information Platform Construction Project
The total investment amount of this project is RMB 30000000 in which RMB 30000000 is
raised. The investment is used to purchase information management software and hardware as well
as computer room facilities. The project planned to upgrade and improve: the information
infrastructure of existing information management system including disaster recovery and
7 / 16Joincare Pharmaceutical Group Industry Co. Ltd. 2022 First Quarterly Report
infrastructure of the server and security equipment; financial management system including
financial sharing system and tax administration system; group management and control system
including HR system and SAP system.
2. Matters about share repurchase
Pursuant to the Resolution on Share Repurchase Scheme by Way of Centralized bidding
transactions and other resolutions considered and approved at the 6th Meeting of the 8th Session of
the Board and the 2021 Fifth Extraordinary General Meeting of the Company on 6 December 2021
and 23 December 2021 it was approved that the Company repurchased company shares by way of
Centralized bidding transactions with its own funds; the total amount of repurchase funds should be
no less than RMB 300 million (inclusive) and no more than RMB 600 million (inclusive); the
repurchase price should be no more than RMB 15/share (inclusive); the repurchase term should be
no more than 12 months from the date when the repurchase scheme was approved by the General
Meeting of the Company. For the details please see the Announcement of Joincare Pharmaceutical
Group Industry Co. Ltd. on the Share Repurchase Scheme by Way of Centralized bidding
transactions (Lin 2021-145) and the Repurchase Report of Joincare Pharmaceutical Group Industry
Co. Ltd. on Share Repurchase by Way of Centralized bidding transactions (Lin 2022-002). On 20
January 2022 the Company initially repurchased 785992 shares by way of Centralized bidding
transactions representing 0.04% of total share capital (1907727908 shares) of the Company. The
aggregate amount of funds used for the repurchase was RMB 9.981 million (including the
transaction costs). See the Announcement of Joincare Pharmaceutical Group Industry Co. Ltd. on
Initial Share Repurchase by Way of Centralized bidding transactions (Lin 2022-004) for details.As of 31 March 2022 the Company initially repurchased 20942771 shares by way of
Centralized bidding transactions representing 1.10% of total share capital (1911733078 shares)
of the Company. The aggregate amount of funds used for the repurchase was RMB 249.97 million
(including the transaction costs). See the Announcement of Joincare Pharmaceutical Group Industry
Co. Ltd. on the Repurchase Progress by way of Centralized bidding transactions (Lin 2022-037)
for details.
3. Matters about Equity Incentives
During the period from 1 January 2022 to 31 March 2022 4005170 shares were granted by
way of independent exercise and registered at the Shanghai Branch of China Securities Depository
and Clearing Corporation Limited with a total of RMB 32227676.96 been paid. As of 31 March
2022 the Company's registered capital after change was RMB 1911733078 and its share capital
8 / 16Joincare Pharmaceutical Group Industry Co. Ltd. 2022 First Quarterly Report
was RMB 1911733078 of which tradable shares subject to selling restrictions were RMB 0
representing 0% of the Company's registered capital and tradable shares subject to no selling
restrictions were RMB 1911733078 representing 100% of the Company's registered capital. The
exercise exerted no material impact on the financial conditions and operating results of the Company.See the Announcement on 2022 Q1 Independent Exercise Results of the 2018 Share Options
Incentive Scheme of Joincare Pharmaceutical Industry Group Co. Ltd. & Changes in Shares (Lin
2022-038) for details.
IV Quarterly Financial Statements
（I）Audit Opinion
□Applicable √N/A（II）Financial statements
9 / 16Joincare Pharmaceutical Group Industry Co. Ltd. 2022 First Quarterly Report
Consolidated Balance Sheet Statement
31 March 2022
Prepared by: Joincare Pharmaceutical Group Industry Co. Ltd.Unit: Yuan Currency: RMB Audit type: Unaudited
Item 31 March 2022 31 December 2021
Current assets:
Monetary funds 12579072007.38 11729230390.98
Financial assets held for trading 130554453.78 184638344.31
Bills receivable 2221923260.75 1977286022.02
Accounts receivable 2897888908.52 2853655551.54
Receivable financing
Prepayments 464654180.19 369232546.29
Other receivables 80180643.34 88053825.12
In which: Interests receivable 362924.63 365873.64
Dividends receivable
Inventories 2029375758.07 2078944387.68
Contract assets
Held-for-sale assets
Non-current assets due within one year 317381.23 317381.23
Other current assets 83883266.43 83986214.37
Total current assets 20487849859.69 19365344663.54
Non-current assets:
Debt investment
Other debt investment
Long-term receivables 266904.13 266904.13
Long-term equity investment 1447659314.56 1419349454.84
Other equity instrument investment 1186338011.05 1408882377.42
Other non-current financial assets
Investment properties 6191475.43 6191475.43
Fixed assets 4779625073.08 4839005169.81
Construction in progress 903828896.94 742998743.75
Productive biological assets
Oil & gas assets
Right-of-use assets 51560715.90 46774759.69
Intangible assets 488051308.06 456782094.80
Development expenses 846825404.25 786993435.71
Goodwills 614468698.73 614468698.73
Long-term prepaid expenses 196182282.29 200715740.93
Deferred income tax assets 548328553.88 552542866.71
Other non-current assets 717916255.16 663584003.80
Total non-current assets 11787242893.46 11738555725.75
Total assets 32275092753.15 31103900389.29
Current liabilities:
Short-term loans 1655807901.10 2518484835.09
Financial liabilities held for trading 211410.89 143302.24
Bills payable 1871975736.48 1582386767.93
10 / 16Joincare Pharmaceutical Group Industry Co. Ltd. 2022 First Quarterly Report
Accounts payable 846260427.00 871553210.51
Receipts in advance 23724198.29
Contract liabilities 124089632.31 234140702.29
Payroll payable 323791427.31 475430823.20
Taxes payable 382548978.08 270618183.41
Other payables 3514175791.66 3292407989.79
In which: Interests payable
Dividends payable 6951984.46 6951984.46
Held-for-sale liabilities
Non-current liabilities due within one year 93590946.07 91576066.33
Other current liabilities 10663325.14 15626224.29
Total current liabilities 8846839774.33 9352368105.08
Non-current liabilities:
Long-term loans 1816661809.48 826780252.78
Bonds payable
Lease liabilities 27215133.45 25071794.32
Long-term payables
Long-term payroll payable
Estimated liabilities
Deferred income 486773175.06 433543352.40
Deferred income tax liabilities 179242425.75 208525905.39
Other non-current liabilities 84000000.00 78000000.00
Total non-current liabilities 2593892543.74 1571921304.89
Total liabilities 11440732318.07 10924289409.97
Owners’ equity (shareholders’ equity):
Paid-in capital (or equity capital) 1911733078.00 1907727908.00
Other equity instruments
In which: Preferred shares
Perpetual capital securities
Capital reserve 2303238441.65 2265357311.92
Less: Treasury shares 472590296.96 222644454.50
Other comprehensive income -87498451.08 5387545.97
Special reserve
Surplus reserve 650230145.70 640821179.08
Undistributed profits 7768862679.28 7223644166.22
Total owners' equity (shareholders’ equity)
attributable to the parent company 12073975596.59 11820293656.69
Minority shareholders' equity 8760384838.50 8359317322.63
Total owners' equity (shareholders’ equity) 20834360435.08 20179610979.32
Total liabilities and owners' equity (shareholders’
equity) 32275092753.15 31103900389.29
Person-in-charge of the Person-in-charge of the Person-in-charge of the
Company: Zhu Baoguo Company’s accounting work: accounting department:
Qiu Qingfeng Qiu Qingfeng
11 / 16Joincare Pharmaceutical Group Industry Co. Ltd. 2022 First Quarterly Report
Consolidated income statement
From January to March 2022
Prepared by: Joincare Pharmaceutical Group Industry Co. Ltd.Unit: Yuan Currency: RMB Audit type: Unaudited
Item 2022 Jan.-Mar. 2021 Jan.-Mar.I. Total operating revenues 4657343538.89 4144871763.27
In which: Operating revenues 4657343538.89 4144871763.27
II. Total operating costs 3650160694.91 3314653870.26
In which: Operating costs 1611006712.60 1448371494.49
Operating tax and surcharges 52198225.41 50752537.45
Selling expenses 1413289256.99 1342825512.04
Administrative expenses 252854561.35 223288755.24
R&D expenses 351331244.23 289399163.64
Finance expenses -30519305.67 -39983592.60
In which: Interest expenses 29854923.66 15859568.04
Interest income 68468649.16 40497552.32
Add: Other income 59138624.91 77577799.31
Investment incomes (enter "-" for loss) 29176808.52 21812732.70
In which: Income from investment in
15204632.53-1982728.44
associates and joint ventures
Income from derecognition of financial
assets at amortized cost
Net exposure hedging gains (enter "-" for
loss)
Income from changes in fair value (enter "-"
-54151999.18-39393074.92
for loss)
Credit impairment loss (enter "-" for loss) 217773.10 -3611272.93
Asset impairment loss (enter "-" for loss) -5309013.21 -22802167.34
Profit on disposal of assets (enter "-" for
-370357.7121927.78
loss)
III. Operating profit (enter "-" for loss) 1035884680.41 863823837.62
Add: Non-operating income 2321933.96 24072371.67
Less: Non-operating expenditures 2084578.34 3257611.14
IV. Total profit (enter "-" for total loss) 1036122036.03 884638598.15
Less: Income tax expenses 173764775.30 126802840.14
V. Net profit (enter "-" for net loss) 862357260.73 757835758.01
(1) Classified by continuing operations
1. Net profit from continuing operations (enter "-"
862357260.73757835758.01
for net loss)
2. Net profit from discontinuing operations (enter
"-" for net loss)
(2) Classified by attribution to ownership
12 / 16Joincare Pharmaceutical Group Industry Co. Ltd. 2022 First Quarterly Report
1. Net profit attributable to shareholders of the
460537813.53366890019.20
parent company (enter "-" for net loss)
2. Profit and loss attributable to minority interests
401819447.20390945738.81
(enter "-" for net loss)
VI. Other comprehensive net income after taxation -106847774.60 -166618134.73
(1) Other comprehensive net income after taxation
-92885997.05-98483184.70
attributable to shareholders of the parent company
1. Other comprehensive income not to be
-75513312.70-81219999.41
reclassified into profit and loss
1) Changes in re-measurement of defined benefit
plans
2) Other comprehensive income not to be
reclassified into profit and loss under the equity
method
3) Changes in fair value of other equity instrument
-75513312.70-81219999.41
investment
4) Changes in fair value of corporate credit risks
2. Other comprehensive income to be reclassified
-17372684.35-17263185.29
into profit and loss
1) Other comprehensive income to be reclassified
into profit and loss under the equity method
2) Changes in fair value of other debt investment
3) Amount of financial assets reclassified into
other comprehensive income
4) Provision for credit impairment of other debt
investment
5) Cash flow hedge reserve
6) Foreign currency translation differences -17372684.35 -17263185.29
7) Others
(2) Other comprehensive net income after taxation
-13961777.55-68134950.03
attributable to minority interests
VII. Total comprehensive income 755509486.13 591217623.29
(1) Total comprehensive income attributable to
367651816.48268406834.51
shareholders of the parent company
(2) Total comprehensive income attributable to
387857669.65322810788.78
minority interests
VIII. Earnings per share
(1) Basic earnings per share (RMB/share) 0.2411 0.1877
(2) Diluted earnings per share (RMB/share) 0.2410 0.1872
Person-in-charge of the Person-in-charge of the Person-in-charge of the
Company: Zhu Baoguo Company’s accounting work: accounting department:
Qiu Qingfeng Qiu Qingfeng
13 / 16Joincare Pharmaceutical Group Industry Co. Ltd. 2022 First Quarterly Report
Consolidated Cash Flow Statement
From January to March 2022
Prepared by: Joincare Pharmaceutical Group Industry Co. Ltd.Unit: Yuan Currency: RMB Audit type: Unaudited
Project 2022 Jan.-Mar. 2021 Jan.-Mar.I. Cash flow from operating activities:
Cash received from sales of goods and services rendered 4614758574.74 3878119048.16
Tax refunds 32240811.32 28034439.16
Other cash received related to operating activities 172771264.97 155840257.54
Subtotal of cash inflow from operating activities 4819770651.03 4061993744.86
Cash paid for purchase of goods and services rendered 1165780579.10 960547682.14
Cash paid to and on behalf of employees 758821581.15 623820018.21
Taxes paid 420627138.84 457863727.21
Other cash paid related to operating activities 1602636874.96 1525112803.05
Subtotal of cash outflow in operating activities 3947866174.05 3567344230.61
Net cash flow from operating activities 871904476.98 494649514.25
II. Cash flows from investing activities:
Cash received from disposal of investments 216970980.42 54739567.55
Cash received on investment income 6832308.83 16991426.46
Net cash received from disposal of fixed assets intangible
346152.00330823.20
assets and other long-term assets
Net cash received from disposal of subsidiaries and other
business units
Other cash received related to investing activities 7668394.07 7743584.00
Subtotal of cash inflow from investing activities 231817835.32 79805401.21
Cash paid for purchase and construction of fixed assets
277850093.60327336656.96
intangible assets and other long-term assets
Cash payments for investments 30338557.45 20000000.00
Net cash paid for acquisition of subsidiaries and other
business units
Other cash paid related to investing activities 1537021.94 1889662.63
Subtotal of cash outflow in investing activities 309725672.99 349226319.59
Net cash flow from investment activities -77907837.67 -269420918.38
III. Cash flow from financing activities:
Cash received from investments 53414701.36 350758135.59
In which: Cash received by subsidiaries from investment of
minority shareholders
Cash received from borrowings 1923486837.26 660000000.00
Other cash received related to financing activities 130847366.53 816504.87
Subtotal of cash inflow from financing activities 2107748905.15 1011574640.46
Cash paid on repayment of debts 1776859803.19 1002984146.53
Cash paid for dividend and profit distribution or interest
19177786.1015889262.19
payment
14 / 16Joincare Pharmaceutical Group Industry Co. Ltd. 2022 First Quarterly Report
In which: Dividends and profit paid by subsidiaries to
minority shareholders
Other cash paid related to financing activities 248996762.52 535456140.59
Subtotal of cash outflow in financing activities 2045034351.81 1554329549.31
Net cash flow from financing activities 62714553.34 -542754908.85
IV. Effect of changes in foreign exchange rates on cash and
-12259201.983666733.44
cash equivalents
V. Net increase in cash and cash equivalents 844451990.66 -313859579.54
Add: Opening balance of cash and cash equivalents 11697518141.18 12122781311.49
VI. Closing balance of cash and cash equivalents 12541970131.84 11808921731.95
Person-in-charge of the Person-in-charge of the Person-in-charge of the
Company: Zhu Baoguo Company’s accounting work: accounting department:
Qiu Qingfeng Qiu Qingfeng
15 / 16Joincare Pharmaceutical Group Industry Co. Ltd. 2022 First Quarterly Report
(III) Information on adjustment to relevant items in the financial statements at the beginning of
the year of first implementation in respect of the new accounting standards adopted for the first time
starting from 2022
□Applicable√N/A
Notice is hereby given.Joincare Pharmaceutical Group Industry Co. Ltd.April 22 2022